Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NXI-S160
- Development stage
- Preclinical
- Lead developer
- NEX-I
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
NXI-S160 is a preclinical-stage antibody-drug conjugate (ADC) being developed by NEX-I in partnership with GC Biopharma. Discovered using NEX-I's proprietary SMRT (Stratified Multi-omics-based Target) platform, the drug targets a specific tumor surface epitope associated with immunosuppressive and standard-of-care-resistant tumor microenvironments (TME). By targeting these epitopes, NXI-S160 aims to overcome resistance to current therapies in various solid tumors. The specific payload and linker technology have not been publicly disclosed, but the program is currently in the candidate selection and preclinical development phase.
Beyond the preview
Go deeper on NXI-S160.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NXI-S160.